Compound Summary
Compound Information
药名: | licochalcone A |
别名: | AIDS-060352; D08GEN; LMPK12120424; 749L227; AN-276; (E)-3-[5-(1,1-Dimethyl-allyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxy-phenyl)-propenone; (2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; (E)-3-[5-(1,1-dimethylallyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; Licochalcone-A, Synthetic; LICOAGROCHACONE A; SCHEMBL114042; HY-N0372; licochalcone a; CS-5603; 4 inverted exclamation marka,4-Dihydroxy-3-; EX-A1193; BRD-K99667445-001-01-4; 2-Propen-1-one, 3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)- (E)-; Licohalconel A; AIDS060352; 3-[5-((E)-1,1-Dimethyl-allyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxy-phenyl)-propenone; (E)-3-(4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one; 3-[5-(1,1-dimethylprop-2-enyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; (E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; (2E)-3-[5-(1,1-dimethylprop-2-en-1-yl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; NP-012615; Q-100677; AK198741; 3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; 3-[5-(1,1-dimethylprop-2-enyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; C21H22O4; 3-Dimethylallyl-4,4'-dihydroxy-6-methoxychalcone; s7828; KAZSKMJFUPEHHW-DHZHZOJOSA-N; (E)-3-[5-(1,1-dimethylprop-2-enyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; BDBM50068270; LS-122598; HSCI1_000078; MolPort-005-945-554; JTV5467968; ZINC3873123; Licochalcone-A; MolPort-044-567-637; (E)-3-[5-(1,1-dimethylprop-2-enyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; V2343; Licochalcone A; 58749-22-7; CCG-208030; Licochalcone A, >=96.0% (HPLC); AB0021119; EBD46703; CHEMBL139702; CHEBI:125689; UNII-JTV5467968; AC1NSXJH; AKOS026673964; A-dimethylallyl-6-methoxychalcone; 2-Propen-1-one, 3-(5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (E)-; (E)-3-[5-(1,1-Dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-2-propen-1-one; BG01626652 |
分子式: | C21H22O4 |
Smiles: | c1(O[H])c([H])c([H])c(C(=O)\C([H])=C([H])/c2c([H])c(C(C([H])=C([H])[H])(C([H])([H])[H])C([H])([H])[H])c(O[H])c([H])c2OC([H])([H])[H])c([H])c1[H] |
成分: | HBIN033093 |
OB_score: | 40.789652 |
CAS_id: | 58749-22-7 |
SymMap_id: | SMIT00053;SMIT02555 |
TCMID_id: | 12760 |
TCMSP_id: | MOL000497 |
PubChem_id: | 5318998 |
化合物对应的植物
| 植物ID | 拉丁名 | 药用植物名 | 药名 | 来源 | 功能与主治 | 使用民族 |
|---|
| TCMBANKHE003728 | Radix Glycyrrhizae | 甘草 | To reinforce the function of the spleen and replenish qi, to remove heat and counteract toxicity, to dispel phlegm and relieve cough, to alleviate spasmodic pain, and to moderate drug actions./1. Its decoction can inhibit intestinal smooth muscles of rabbins in vitro, but glycyrrhizin and glycyrrhetinic acid have no this effect.2. Possessing an adrenocorticomimetic effect.3. Its extract and glycyrrhizin exerts a detoxifying effect.4. Antitussive and antiasthmatic. 5. Glycyrrhizin has anti-inflammatory effect similar to hydrocortisone. | |||
| TCMBANKHE004528 | Glycyrrhiza kansuensis | 黄甘草 | See Glycyrrhiza uralensis ./See Glycyrrhiza uralensis. | |||
| TCMBANKHE007546 | Glycyrrhiza inflata | 胀果甘草 | See Glycyrrhiza uralensis ./See Glycyrrhiza uralensis. | |||
| TCMBANKHE007721 | Exocarpium Benincasae | 冬瓜皮 | 1. To promote diuresis to relieve edema. 2. To clear summer-heat./Edema, inhibited urination [=dysuria], diarrhea, swelling of sores. | |||
| TCMBANKHE008315 | Cortex erythrie | 海桐皮 | 1. To dispel wind and dampness; 2. To clear the meridians/Wind-damp impediment, pain in lumbus and knees, scab sore, lichen, eczema. | |||
| TCMBANKHE007847 | Caulis Millettiae; Caulis spatholobi | 鸡血藤 | To enrich the blood, to activate blood circulation, and to remove obstruction of the channels and collaterals./Treatment of menstrual disorders, anemia, numbness and paralysis, rheumatic arthralgia. |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
| TCMBANKDI000089 | Asthma | disease | Respiratory Tract Diseases; Immune System Diseases | 31226782 |
| TCMBANKDI006871 | Hyperplasia | phenotype | Pathological Conditions, Signs and Symptoms | 31226782 |
| TCMBANKDI030572 | Respiratory Hypersensitivity | phenotype | Respiratory Tract Diseases; Immune System Diseases | 31226782 |
化合物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 |
|---|
| TCMBANKGE000181 | PIM1 | PIM | Pim-1 proto-oncogene, serine/threonine kinase |
| TCMBANKGE000201 | ESR1 | ER; ESR; ESRA; ESTRR; Era; NR3A1 | estrogen receptor 1 |
| TCMBANKGE000204 | CXCL8 | GCP-1; GCP1; IL8; LECT; LUCT; LYNAP; MDNCF; MONAP; NAF; NAP-1; NAP1; SCYB8 | C-X-C motif chemokine ligand 8 |
| TCMBANKGE000205 | NOS2 | HEP-NOS; INOS; NOS; NOS2A | nitric oxide synthase 2 |
| TCMBANKGE000286 | GSK3B | - | glycogen synthase kinase 3 beta |
| TCMBANKGE000309 | SCN5A | CDCD2; CMD1E; CMPD2; HB1; HB2; HBBD; HH1; ICCD; IVF; LQT3; Nav1.5; PFHB1; SSS1; VF1 | sodium voltage-gated channel alpha subunit 5 |
| TCMBANKGE000360 | CCNA2 | CCN1; CCNA | cyclin A2 |
| TCMBANKGE000476 | NCOA2 | GRIP1; KAT13C; NCoA-2; SRC2; TIF2; bHLHe75 | nuclear receptor coactivator 2 |
| TCMBANKGE000478 | CHEK1 | CHK1 | checkpoint kinase 1 |
| TCMBANKGE000633 | ADRB2 | ADRB2R; ADRBR; B2AR; BAR; BETA2AR | adrenoceptor beta 2 |
| TCMBANKGE000701 | ESR2 | ER-BETA; ESR-BETA; ESRB; ESTRB; Erb; NR3A2; ODG8 | estrogen receptor 2 |
| TCMBANKGE000723 | FOSL2 | FRA2 | FOS like 2, AP-1 transcription factor subunit |
| TCMBANKGE000813 | DPP4 | ADABP; ADCP2; CD26; DPPIV; TP103 | dipeptidyl peptidase 4 |
| TCMBANKGE000824 | RB1 | OSRC; PPP1R130; RB; p105-Rb; p110-RB1; pRb; pp110 | RB transcriptional corepressor 1 |
| TCMBANKGE000903 | PTGS1 | COX1; COX3; PCOX1; PES-1; PGG/HS; PGHS-1; PGHS1; PHS1; PTGHS | prostaglandin-endoperoxide synthase 1 |
| TCMBANKGE000938 | CDK2 | CDKN2; p33(CDK2) | cyclin dependent kinase 2 |
| TCMBANKGE001045 | CCND1 | BCL1; D11S287E; PRAD1; U21B31 | cyclin D1 |
| TCMBANKGE001073 | PTGS2 | COX-2; COX2; GRIPGHS; PGG/HS; PGHS-2; PHS-2; hCox-2 | prostaglandin-endoperoxide synthase 2 |
| TCMBANKGE001166 | BCL2 | Bcl-2; PPP1R50 | BCL2 apoptosis regulator |
| TCMBANKGE001170 | CDK4 | CMM3; PSK-J3 | cyclin dependent kinase 4 |
| TCMBANKGE001178 | STAT3 | ADMIO; ADMIO1; APRF; HIES | signal transducer and activator of transcription 3 |
| TCMBANKGE001184 | RELA | CMCU; NFKB3; p65 | RELA proto-oncogene, NF-kB subunit |
| TCMBANKGE001185 | PPARG | CIMT1; GLM1; NR1C3; PPARG1; PPARG2; PPARG5; PPARgamma | peroxisome proliferator activated receptor gamma |
| TCMBANKGE001202 | MAPK14 | CSBP; CSBP1; CSBP2; CSPB1; EXIP; Mxi2; PRKM14; PRKM15; RK; SAPK2A; p38; p38ALPHA | mitogen-activated protein kinase 14 |
| TCMBANKGE001203 | MAPK1 | ERK; ERK-2; ERK2; ERT1; MAPK2; P42MAPK; PRKM1; PRKM2; p38; p40; p41; p41mapk; p42-MAPK | mitogen-activated protein kinase 1 |
| TCMBANKGE001506 | ADRA1B | ADRA1; ALPHA1BAR | adrenoceptor alpha 1B |
| TCMBANKGE003300 | EIF6 | CAB; EIF3A; ITGB4BP; b(2)gcn; eIF-6; p27(BBP); p27BBP | eukaryotic translation initiation factor 6 |
| TCMBANKGE004266 | AR | AIS; AR8; DHTR; HUMARA; HYSP1; KD; NR3C4; SBMA; SMAX1; TFM | androgen receptor |
| TCMBANKGE005535 | CHRM1 | HM1; M1; M1R | cholinergic receptor muscarinic 1 |
| TCMBANKGE006339 | CA2 | CA-II; CAC; CAII; Car2; HEL-76; HEL-S-282 | carbonic anhydrase 2 |
| TCMBANKGE011079 | PRSS1 | TRP1; TRY1; TRY4; TRYP1 | serine protease 1 |
| TCMBANKGE012155 | SLC6A3 | DAT; DAT1; PKDYS; PKDYS1 | solute carrier family 6 member 3 |
滇ICP备16009434号-1 |
Dai SX Lab